GLP-1 / BPC-157 – Freebase Reconstituted
GLP-1 / BPC-157 – Freebase Reconstituted
Share
The combination of Semaglutide, a synthetic glucagon-like peptide-1 (GLP-1) analog, with BPC-157, known as Body Protective Compound 157, represents a groundbreaking development in peptide research. This GLP-1 / BPC-157 blend is researched to optimize diabetes management, weight control, and enhance recovery, leveraging the distinct properties of both peptides.
- 100% Secure Online Payments
- 99% Purity Guarantee
- Free Shipping Over $500
Peptide Product Usage
PEPTIDE PRODUCTS ARE INTENDED AS A RESEARCH CHEMICAL ONLY.
This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
AOD-9604
Introduction to AOD 9604
AOD 9604 is a peptide representing a specific human growth hormone fragment (hGH). Originally developed in the 1990s, its primary focus was on combating obesity. This peptide has garnered significant interest in the scientific community due to its potential effects on fat metabolism, obesity management, and tissue regeneration.
Exploring the Research on AOD 9604
Lipolytic Activity in Animal Models
- Studies in Obese Mice: Research involving obese mice demonstrated that AOD 9604 might enhance lipolysis, the process of breaking down stored fats. The peptide was observed to increase levels of lipolytic receptors, particularly beta(3)-AR, in fat cells, suggesting a mechanism of action similar to that of hGH.
- Further Insights: Subsequent studies, including those on mice with disabled lipolytic receptors, suggested that AOD 9604's effects might extend beyond receptor interaction, potentially involving increased energy expenditure and fat oxidation.
Research in Obese Zucker Rats
- A study conducted on obese Zucker rats, where AOD 9604 was administered daily for 19 days, showed a significant reduction in weight compared to placebo groups. This weight loss was accompanied by increased lipolytic activity in adipose tissues without notable disruption to insulin sensitivity.
AOD 9604 and Obesity Management
- Clinical Trials: In 2004, a clinical trial involving 300 obese subjects over 12 weeks revealed consistent weight loss rates among participants. The trial also noted minor improvements in cholesterol profiles and glucose tolerance levels, suggesting potential benefits in managing obesity.
Potential in Tissue Regeneration
- Cartilage Repair Research: Studies, including those involving rabbits, indicated that AOD 9604 might aid in cartilage regeneration, especially when combined with hyaluronic acid.
- Stem Cell Differentiation: In vitro studies have suggested a role for AOD 9604 in enhancing the differentiation of adipose mesenchymal stem cells into bone cells, highlighting its potential in cellular differentiation processes.
- Chondrocyte Activity: Research has shown that AOD 9604 may increase proteoglycan and collagen production in bovine chondrocytes, which is essential for cartilage tissue health.
AOD 9604 in Cancer Research
- Enhancing Chemotherapy Efficacy: Studies have explored the potential of AOD 9604 in enhancing the efficacy of chemotherapy agents, such as doxorubicin. Research involving chitosan nanoparticles indicated that AOD 9604 might improve doxorubicin binding to breast cancer cell protein targets, potentially increasing its anti-proliferative activity.
Conclusion
The research on AOD 9604 highlights its potential as a multifaceted peptide with applications in fat metabolism, obesity management, tissue regeneration, and cancer therapy. However, it is important to approach these findings cautiously, recognizing the need for further research and clinical trials to understand the peptide's mechanisms and potential therapeutic applications fully. The information provided here is for research and educational purposes only and is not intended for direct human application.
References:
- Mark Heffernan, Roger J. Summers, Anne Thorburn, Esra Ogru, Robert Gianello, Woei-Jia Jiang, Frank M. Ng, The Effects of Human GH and Its Lipolytic Fragment (AOD 9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β 3-AR Knock-Out Mice, Endocrinology, Volume 142, Issue 12, 1 December 2001, Pages 5182–5189. https://pubmed.ncbi.nlm.nih.gov/11713213/
- Moré, M. I., & Kenley, D. (2014). Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism, 4(3), 64-77.
- Frank M. Ng, J Sun et.al, Metabolic Studies of a Synthetic Lipolytic Domain (AOD 9604) of Human Growth Hormone, Hormone Research, February 2000.
- News, Medical and Life Sciences, Obesity drug codenamed AOD 9604 highly successful in trials, 16 December 2004.
- Dong Rak Kwon and GI Young Park, Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model, Annals of Clinical and Laboratory Science, Volume 45, July-August 2015.
- Habibullah, M. M., Mohan, S., Syed, N. K., Makeen, H. A., Jamal, Q. M. S., Alothaid, H., Bantun, F., Alhazmi, A., Hakamy, A., Kaabi, Y. A., Samlan, G., Lohani, M., Thangavel, N., & Al-Kasim, M. A. (2022). Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug design, development and therapy, 16, 1963–1974. https://doi.org/10.2147/DDDT.S367586